Mengni (Nina) Cao

Private Equity / Cross-Border M&A / Joint Ventures

• Represented The Jordan Company in its acquisition through a newly formed company of four global business segments of Trimble Inc. (Protempis, a timing and synchronization solutions company; Loadrite, a weighing solutions company; Spectra Precision, a manufacturer of precision laser instruments; and SECO, a surveying equipment and instruments provider).
• Represented MUFG (as the lead investor, structuring and placement agent) in AT&T Inc.’s series of sales of limited membership interests in AT&T Fiber Investment, LLC (as the issuer), an subsidiary of AT&T, for an aggregate investment amount of $6.25 billion.  As part of the transactions, AT&T and its affiliates contributed financial assets and additional assets related to fiber optic cables to the issuer, to satisfy certain negative and affirmative covenants requiring the issuer to hold, among other things, certain minimum value of permitted assets.
• Represented Tsingshan Group in its acquisition of the DRAP business line of Allegheny Technologies Incorporated (NYSE: ATI) by forming a joint venture.
• Represented a global maritime company in its strategic acquisitions of a majority stake in three Indian aquatic products processing companies.
• Represented Yixing Capital in its acquisition of global furniture company Lexington Home Brands, Inc.
• Represented a group of private equity funds in their joint acquisition of a California-based video producing company.
• Represented ZTE Corporation in its acquisition of a controlling stake in a California-based commercial physical and biological research company.
• Represented a California software system designing and development company in its venture capital financing, restructuring and re-domiciliation to Cayman Islands through a reverse triangular merger.

Life Science / Health Care / Biotech

• Represented Takeda in its in-license of exclusive worldwide (ex-China) rights to Fruquintinib from HUTCHMED (China) Limited for an upfront payment of $400 million, milestone payments of up to $730 million and royalties on net sales.
• Represented Joinn Laboratories China Co. Ltd. in its acquisition of Biomedical Research Models, a Boston-based pre-clinical CRO.
• Represented a Chinese publicly listed biotech pharmaceutical company in its investment in a Maryland-based therapeutical company.
• Represented a private equity fund in its acquisition of an Alabama-based molecular diagnostic company.
• Represented Thalys Medical Technology Group in its investment in LevitasBio, a Stanford spinout commercializing a cell purification and separation technology based on magnetic levitation.
• Represented a global PE firm in its serial investments in three biotechnology companies.
• Represented a Chinese publicly listed medical equipment manufacturing and distributing company in its investment in a California-based molecular diagnostics company.
• Represented ZTE Corporation in its acquisition of a controlling stake in a California-based commercial physical and biological research company.

Insurance / Reinsurance

• Represented global commercial insurance and reinsurance company AXA XL in the sale of its U.S. crop insurance business, which included the sale of AXA XL’s wholly-owned subsidiary Global Ag as well as transfer of AXA XL’s crop insurance policies through reinsurance, assignment and assumption, and transfer of administration.